Patent · US Active

Fully human antibodies that bind to vascular endothelial growth factor receptor 2 (VEGFR2) and methods of use thereof for treatment

US12084503B2 · kind B2 · utility

2Cited by

0References

18Claims

0Family size

Assignee

Vivasor, Inc. · US

Inventors

Randy Gastwirt · San Diego, US
Heyue Zhou · San Diego, US
John Dixon Gray · Union, US
Guodi Lu · San Diego, US

Key dates

Filing date	Jul 29, 2021
Grant date	Sep 10, 2024
Priority date	—
Expiry date	Oct 25, 2041

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/94
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

There is disclosed compositions and methods relating to anti-VEGFR2 antibodies. More specifically, there is disclosed fully human antibodies that bind VEGFR2, VEGFR2-binding fragments and derivatives of such antibodies, and VEGFR2-binding polypeptides comprising such fragments. Further still, there is disclosed antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having various cancers.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.